AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia

Blood

Volumn 123, Issue 6, 2014, Pages 905-913

  Keeton, Erika K ^a   McEachern, Kristen ^a   Dillman, Keith S ^a   Palakurthi, Sangeetha ^a   Cao, Yichen ^a   Grondine, Michael R ^a   Kaur, Surinder ^b,c   Wang, Suping ^a   Chen, Yuching ^a   Wu, Allan ^a   Shen, Minhui ^a   Gibbons, Francis D ^a   Lamb, Michelle L ^a   Zheng, Xiaolan ^a   Stone, Richard M ^d   DeAngelo, Daniel J ^d   Platanias, Leonidas C ^b,c   Dakin, Les A ^a   Chen, Huawei ^a   Lyne, Paul D ^a   Huszar, Dennis ^a   more..

^a ASTRAZENECA   (United Kingdom)

^b NORTHWESTERN UNIVERSITY   (United States)

^c JESSE BROWN VA MEDICAL CENTER   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AZD 1208; AZD1208; CASPASE 3; CYTARABINE; FLT3 LIGAND; INITIATION FACTOR 4E BINDING PROTEIN 1; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN BAD; PROTEIN BCL 2; PROTEIN KINASE PIM 1; PROTEIN P27; PROTEIN S6; S6 KINASE; STAT5 PROTEIN; UNCLASSIFIED DRUG; BIPHENYL DERIVATIVE; PIM1 PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; THIAZOLIDINE DERIVATIVE;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW CELL; CANCER INHIBITION; CELL ASSAY; CELL CYCLE ARREST; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; ENZYME INHIBITION; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; MUTANT; MYELOID LEUKEMIA CELL LINE; NONHUMAN; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; TUMOR XENOGRAFT; UPREGULATION; ANIMAL; CELL CYCLE; DRUG ANTAGONISM; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYMOLOGY; METABOLISM; PATHOLOGY; SCID MOUSE; TISSUE DISTRIBUTION; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BIPHENYL COMPOUNDS; BLOTTING, WESTERN; CELL CYCLE; CELL PROLIFERATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MICE; MICE, SCID; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-PIM-1; THIAZOLIDINES; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED;

EID: 84896367733     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-04-495366     Document Type: Article

References (37)

1. Cuypers HT, Selten G, Quint W, et al. Murine leukemia virus-induced T-cell lymphomagenesis: integration of proviruses in a distinct chromosomal region. Cell. 1984;37(1):141-150. (Pubitemid 14079845)
2. Breuer ML, Cuypers HT, Berns A. Evidence for the involvement of pim-2, a new common proviral insertion site, in progression of lymphomas. EMBO J. 1989;8(3):743-748.
3. Amson R, Sigaux F, Przedborski S, Flandrin G, Givol D, Telerman A. The human protooncogene product p33pim is expressed during fetal hematopoiesis and in diverse leukemias. Proc Natl Acad Sci USA. 1989;86(22):8857-8861. (Pubitemid 20010324)
4. Cohen AM, Grinblat B, Bessler H, et al. Increased expression of the hPim-2 gene in human chronic lymphocytic leukemia and non-Hodgkin lymphoma. Leuk Lymphoma. 2004;45(5):951-955. (Pubitemid 38444671)
5. Mizuki M, Schwable J, Steur C, et al. Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations. Blood. 2003;101(8):3164-3173. (Pubitemid 36858011)
6. Asano J, Nakano A, Oda A, et al. The serine/threonine kinase Pim-2 is a novel anti-apoptotic mediator in myeloma cells. Leukemia. 2011;25(7):1182-1188.
7. Kim KT, Baird K, Davis S, et al. Constitutive Fms-like tyrosine kinase 3 activation results in specific changes in gene expression in myeloid leukaemic cells. Br J Haematol. 2007;138(5):603-615. (Pubitemid 47206718)
8. Kim KT, Baird K, Ahn JY, et al. Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival. Blood. 2005;105(4):1759-1767. (Pubitemid 40223700)
9. Bachmann M, Möröy T. The serine/threonine kinase Pim-1. Int J Biochem Cell Biol. 2005;37(4):726-730. (Pubitemid 40202995)
10. Zhu N, Ramirez LM, Lee RL, Magnuson NS, Bishop GA, Gold MR. CD40 signaling in B cells regulates the expression of the Pim-1 kinase via the NF-kappa B pathway. J Immunol. 2002;168(2):744-754. (Pubitemid 34049575)
11. Hu YL, Passegué E, Fong S, Largman C, Lawrence HJ. Evidence that the Pim1 kinase gene is a direct target of HOXA9. Blood. 2007;109(11):4732-4738. (Pubitemid 46827765)
12. Fox CJ, Hammerman PS, Cinalli RM, Master SR, Chodosh LA, Thompson CB. The serine/threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor. Genes Dev. 2003;17(15):1841-1854. (Pubitemid 36944562)
13. Qian KC, Wang L, Hickey ER, et al. Structural basis of constitutive activity and a unique nucleotide binding mode of human Pim-1 kinase. J Biol Chem. 2005;280(7):6130-6137. (Pubitemid 40280098)
14. Nawijn MC, Alendar A, Berns A. For better or for worse: the role of Pim oncogenes in tumorigenesis. Nat Rev Cancer. 2011;11(1):23-34.
15. Aho TL, Sandholm J, Peltola KJ, Mankonen HP, Lilly M, Koskinen PJ. Pim-1 kinase promotes inactivation of the pro-apoptotic Bad protein by phosphorylating it on the Ser112 gatekeeper site. FEBS Lett. 2004;571(1-3):43-49. (Pubitemid 38992921)
16. Yan B, Zemskova M, Holder S, et al. The PIM-2 kinase phosphorylates BAD on serine 112 and reverses BAD-induced cell death. J Biol Chem. 2003;278(46):45358-45367. (Pubitemid 37432672)
17. Macdonald A, Campbell DG, Toth R, McLauchlan H, Hastie CJ, Arthur JS. Pim kinases phosphorylate multiple sites on Bad and promote 14-3-3 binding and dissociation from Bcl-XL. BMC Cell Biol. 2006;7:1.
18. Zhang F, Beharry ZM, Harris TE, et al. PIM1 protein kinase regulates PRAS40 phosphorylation and mTOR activity in FDCP1 cells. Cancer Biol Ther. 2009;8(9):846-853.
19. Tamburini J, Green AS, Bardet V, et al. Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia. Blood. 2009;114(8):1618-1627.
20. Schatz JH, Oricchio E, Wolfe AL, et al. Targeting cap-dependent translation blocks converging survival signals by AKT and PIM kinases in lymphoma. J Exp Med. 2011;208(9):1799-1807.
21. Mikkers H, Nawijn M, Allen J, et al. Mice deficient for all PIM kinases display reduced body size and impaired responses to hematopoietic growth factors. Mol Cell Biol. 2004;24(13):6104-6115. (Pubitemid 38787993)
22. Dakin LA, Block MH, Chen H, et al. Discovery of novel benzylidene-1,3-thiazolidine-2,4-diones as potent and selective inhibitors of the PIM-1, PIM-2, and PIM-3 protein kinases. Bioorg Med Chem Lett. 2012;22(14):4599-4604.
23. Kaur S, Sassano A, Dolniak B, et al. Role of the Akt pathway in mRNA translation of interferon-stimulated genes. Proc Natl Acad Sci USA. 2008;105(12):4808-4813. (Pubitemid 351753828)
24. Carayol N, Vakana E, Sassano A, et al. Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells. Proc Natl Acad Sci USA. 2010;107(28):12469- 12474.
25. Altman JK, Sassano A, Kaur S, et al. Dual mTORC2/mTORC1 targeting results in potent suppressive effects on acute myeloid leukemia (AML) progenitors. Clin Cancer Res. 2011;17(13):4378-4388.
26. Morishita D, Katayama R, Sekimizu K, Tsuruo T, Fujita N. Pim kinases promote cell cycle progression by phosphorylating and down-regulating p27Kip1 at the transcriptional and posttranscriptional levels. Cancer Res. 2008;68(13):5076-5085.
27. Zhang Y, Wang Z, Li X, Magnuson NS. Pim kinase-dependent inhibition of c-Myc degradation. Oncogene. 2008;27(35):4809-4819.
28. Gingras AC, Raught B, Gygi SP, et al. Hierarchical phosphorylation of the translation inhibitor 4E-BP1. Genes Dev. 2001;15(21):2852-2864. (Pubitemid 33042055)
29. Ruvinsky I, Sharon N, Lerer T, et al. Ribosomal protein S6 phosphorylation is a determinant of cell size and glucose homeostasis. Genes Dev. 2005;19(18):2199-2211. (Pubitemid 41330321)
30. Fingar DC, Salama S, Tsou C, Harlow E, Blenis J. Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev. 2002;16(12):1472-1487. (Pubitemid 34686329)
31. Ohanna M, Sobering AK, Lapointe T, et al. Atrophy of S6K1(-/-) skeletal muscle cells reveals distinct mTOR effectors for cell cycle and size control. Nat Cell Biol. 2005;7(3):286-294. (Pubitemid 40331130)
32. Dowling RJ, Topisirovic I, Alain T, et al. mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs. Science. 2010;328(5982):1172-1176.
33. Fathi AT, Arowojolu O, Swinnen I, et al. A potential therapeutic target for FLT3-ITD AML: PIM1 kinase. Leuk Res. 2012;36(2):224-231.
34. Chen LS, Redkar S, Taverna P, Cortes JE, Gandhi V. Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia. Blood. 2011;118(3):693-702.
35. Hospital MA, Green AS, Lacombe C, Mayeux P, Bouscary D, Tamburini J. The FLT3 and Pim kinases inhibitor SGI-1776 preferentially target FLT3-ITD AML cells. Blood. 2012;119(7):1791-1792.
36. Danial NN. BAD: undertaker by night, candyman by day. Oncogene. 2008;27(Suppl 1):S53-S70.
37. Lu J, Zavorotinskaya T, Dai Y, et al. Pim2 is required for maintaining multiple myeloma cell growth through modulating TSC2 phosphorylation. Blood . 2013;122(9):1610-1620.